Centene armodafinil (Nuvigil) Coverage Update

Coverage Criteria

Initial Therapy - Narcolepsy

Covered when ALL of the following are met:

Narcolepsy initial criteria: 1. Diagnosis of narcolepsy; 2. Prescribed by or in consultation with a neurologist or sleep medicine specialist; 3. Age ≥ 17 years; 4. If request is for brand Nuvigil, member must use generic armodafinil unless contraindicated or clinically significant adverse effects are experienced; 5. Failure of a 1-month trial of one of the following generic CNS stimulant-containing agents at up to maximally indicated doses unless contraindicated or clinically significant adverse effects are experienced: amphetamine, dextroamphetamine, or methylphenidate; 6. Dose does not exceed both: a) 250 mg per day and b) 1 tablet per day.age >=17; dose <=250 mg/day; <=1 tablet/day

Prior authorization may be required for CNS stimulants; IL HIM step therapy exception applies per IL HB 5395.

Initial Therapy - Obstructive Sleep Apnea

Covered when ALL of the following are met:

OSA initial criteria: 1. Diagnosis of obstructive sleep apnea (OSA); 2. Age ≥ 17 years; 3. Documented residual sleepiness despite compliant positive airway pressure therapy (e.g., CPAP, BiPAP) used as monotherapy; 4. Armodafinil (Nuvigil) is prescribed concurrently with continued use of positive airway pressure therapy (e.g., CPAP, BiPAP); 5. If request is for brand Nuvigil, member must use generic armodafinil unless contraindicated or clinically significant adverse effects are experienced; 6. Dose does not exceed both: a) 250 mg per day and b) 1 tablet per day.age >=17; dose <=250 mg/day; <=1 tablet/day

Documentation must demonstrate concurrent PAP use; IL HIM step therapy exception per IL HB 5395 referenced.

Initial Therapy - Shift Work Disorder

Covered when ALL of the following are met:

SWD initial criteria: 1. Diagnosis of shift work disorder (SWD); 2. Age ≥ 17 years; 3. If request is for brand Nuvigil, member must use generic armodafinil unless contraindicated or clinically significant adverse effects are experienced; 4. Dose does not exceed both: a) 150 mg per day and b) 1 tablet per day.age >=17; dose <=150 mg/day; <=1 tablet/day

Approval duration: 12 months.

Initial Therapy - MS-associated fatigue (off-label)

Covered when ALL of the following are met:

MS-associated fatigue initial criteria: 1. Diagnosis of MS-associated fatigue; 2. Age ≥ 17 years; 3. Failure of 200 mg/day of amantadine and ≥ 10 mg/day of methylphenidate unless contraindicated or clinically significant adverse effects are experienced; 4. If request is for brand Nuvigil, member must use generic armodafinil unless contraindicated or clinically significant adverse effects are experienced; 5. Dose does not exceed both: a) 250 mg per day and b) 1 tablet per day.age >=17; dose <=250 mg/day; <=1 tablet/day

This is an off-label indication with step therapy requirements; IL HIM step therapy exception per IL HB 5395 referenced.

Continuation Therapy

Covered when ALL of the following are met:

Continuation criteria: 1. Member meets one of the following: a) currently receiving medication via Centene benefit or previously met initial approval criteria; b) member is currently receiving medication and is enrolled in a state/product with continuity of care regulations; 2. Member is responding positively to therapy; 3. For OSA, armodafinil is prescribed concurrently with continued use of positive airway pressure therapy (e.g., CPAP, BiPAP); 4. If request is for brand Nuvigil, member must use generic armodafinil unless contraindicated or clinically significant adverse effects are experienced; 5. If request is for a dose increase, new dose does not exceed indication-specific maximums: a) Narcolepsy, OSA, MS-associated fatigue — 250 mg/day and 1 tablet/day; b) SWD — 150 mg/day and 1 tablet/day.dose limits per indication

Approval duration usually 12 months.

Non–FDA approved (off‑label) indications for armodafinil that are not specifically addressed in this policy will not be authorized unless the provider submits sufficient supporting documentation demonstrating efficacy and safety per applicable off‑label use policies: CP.CPA.09 (commercial), HIM.PA.154 (Health Insurance Marketplace/ICHRA), or CP.PMN.53 (Medicaid).

Use of armodafinil is contraindicated in patients with a known hypersensitivity to modafinil or armodafinil. Requests for therapy in such patients are not authorized and may be denied.

Initial Therapy

Initial therapy

Covered when ALL of the following are met:

Initial therapy consolidated criteria: 1. Age ≥ 17 years for all indications; 2. For narcolepsy, treatment must be prescribed by or in consultation with a neurologist or sleep medicine specialist; 3. If request is for brand Nuvigil, member must use generic armodafinil unless contraindicated or clinically significant adverse effects are experienced; 4. Prior trial and failure requirements as indicated: a) Narcolepsy — 1-month trial of a generic CNS stimulant (amphetamine, dextroamphetamine, or methylphenidate) at maximally indicated doses unless contraindicated; b) MS-associated fatigue (off-label) — failure of amantadine 200 mg/day and ≥10 mg/day methylphenidate unless contraindicated; c) Step therapy requirements do not apply for Illinois HIM requests per IL HB 5395; 5. Indication-specific dosing limits: a) Narcolepsy, OSA, MS-associated fatigue — maximum 250 mg/day and 1 tablet/day; b) SWD — maximum 150 mg/day and 1 tablet/day; 6. Prior authorization is required and approval is granted when the above indication-specific criteria and dosing limits are met.age >=17; dose limits per indication

Specialist involvement required for narcolepsy; generic-first preference; prior authorization and step therapy notes apply, with IL HIM exceptions per IL HB 5395.

Continuation Therapy

Continuation therapy

Covered when ALL of the following are met:

Continuation therapy consolidated: 1. Member is currently receiving therapy via Centene benefit or previously met initial approval criteria (continuity of care may apply per state/product addendums); 2. Member demonstrates positive clinical response to armodafinil; 3. For OSA, continued concurrent use of positive airway pressure therapy is required; 4. Generic armodafinil must be used when possible unless contraindicated or significant adverse effects occur; 5. Dose and any dose increases must not exceed indication-specific maximums: a) Narcolepsy, OSA, MS-associated fatigue — 250 mg/day and 1 tablet/day; b) SWD — 150 mg/day and 1 tablet/day.dose limits per indication

Approval duration typically 12 months; documentation of response and PAP use (for OSA) may be required for prior authorization.

Provider Actions & Requirements

Prior Authorization

Prior Authorization Required

Prior authorization and step therapy may be required for armodafinil (Nuvigil). For certain indications a trial/failure of specified generic alternatives is required before brand Nuvigil will be approved; requests for brand Nuvigil must use generic armodafinil unless contraindicated or clinically significant adverse effects are experienced.

Prior authorization may be required for CNS stimulants.
If request is for brand Nuvigil, member must use generic armodafinil unless contraindicated or clinically significant adverse effects are experienced.

Documentation Required

Documentation Requirement

Providers must submit supporting clinical documentation to demonstrate that the member meets all approval criteria. Failure to provide required documentation may result in denial or delay of the prior authorization request.

Acceptable documentation includes office chart notes, sleep study reports, CPAP/BiPAP adherence logs, relevant lab results, and consultation notes.

Step Therapy

Indication	Step therapy required (trial & failure)	Acceptable agents / trial definition	Exceptions / notes
Narcolepsy	Yes — trial and failure required prior to approval of brand when generic available	One-month trial of a generic CNS stimulant-containing agent at up to maximally indicated doses: amphetamine, dextroamphetamine, or methylphenidate	If request is for brand Nuvigil, member must use generic armodafinil unless contraindicated or clinically significant adverse effects; IL HIM step therapy exception applies as of 1/1/2026
MS-associated fatigue (off-label)	Yes — trial and failure required prior to approval	Failure of amantadine 200 mg/day and methylphenidate ≥10 mg/day unless contraindicated or clinically significant adverse effects	This is an off‑label indication; IL HIM step therapy exception applies as of 1/1/2026
Shift Work Disorder (SWD)	Not specified as requiring CNS stimulant step therapy in policy language for SWD (step therapy references focus on narcolepsy and MS-fatigue)	Policy requires generic-first preference for brand requests (use generic armodafinil unless contraindicated)	Maximum dose for SWD is 150 mg/day; approval duration typically 12 months

Jurisdiction / Line of Business	Bypass applied?	Statutory reference / effective date	Notes
Illinois Health Insurance Marketplace (IL HIM)	Yes — step therapy requirement does not apply	IL HB 5395 — step therapy requirement exempt as of 1/1/2026	Policy explicitly documents the IL HIM bypass; applies to step therapy requirements for narcolepsy and MS-fatigue per policy updates

Coding & Dosing Limits

inv-08: Maximum daily dose

Maximum daily dose — narcolepsy250 mg per day; also limited to 1 tablet per day

Maximum daily dose — obstructive sleep apnea (OSA)250 mg per day; also limited to 1 tablet per day

Maximum daily dose — MS-associated fatigue (off-label)250 mg per day; also limited to 1 tablet per day

Maximum daily dose — shift work disorder (SWD)150 mg per day; also limited to 1 tablet per day

Quantity Limits

inv-24: Armodafinil (Nuvigil) — quantity limit / days supply rules

Quantity limit (tablets/day)1 tablet per day

Days supply / approval durationTypical approval duration: 12 months (Medicaid/HIM/ICHRA and Commercial per criteria)

Available tablet strengths50 mg, 150 mg, 200 mg, 250 mg

Definitions & Abbreviations

inv-18: Abbreviations/therapeutic alternatives

CPAPContinuous positive airway pressure (CPAP)

BiPAPBilevel positive airway pressure (BiPAP)

MS-associated fatigue (definition)Fatigue related to multiple sclerosis (MS) — addressed as an off-label indication with step-therapy requirements

Therapeutic alternatives (examples)Preferred alternatives include generic CNS stimulants such as amphetamine, dextroamphetamine, or methylphenidate; amantadine is an alternative for MS-related fatigue per appendix

inv-19: Known hypersensitivity to modafinil or armodafinil — contra indication definition

Known hypersensitivity — definitionContraindication: known hypersensitivity to modafinil or armodafinil

Background

Armodafinil is a wakefulness‑promoting agent indicated for treatment of excessive sleepiness associated with narcolepsy, obstructive sleep apnea (OSA) (for residual excessive sleepiness despite positive airway pressure therapy), and shift work disorder (SWD). For OSA it is intended as adjunctive therapy when members continue maximal positive airway pressure treatment. Typical dosing ranges permit up to 250 mg/day for narcolepsy and OSA and up to 150 mg/day for SWD, with available tablet strengths of 50, 150, 200, and 250 mg.

Revision History

2026-03-26Material updateLatest

Added requirement for OSA that armodafinil (Nuvigil) be prescribed concurrently with continued use of positive airway pressure therapy and revised CPAP requirement to allow any positive airway pressure therapy (e.g., BiPAP); added ICHRA line of business.

2025-04-07Material update

Added step therapy bypass for Illinois Health Insurance Marketplace (IL HIM) per IL HB 5395.

2009-08-01Effective date

OpenPayer

Clinical Policy: Armodafinil (Nuvigil)

Coverage Criteria

Initial Therapy

Continuation Therapy

Provider Actions & Requirements

Step Therapy

Coding & Dosing Limits

Quantity Limits

Definitions & Abbreviations

Background

Revision History